NMRA250117C22500
- 0.05
- +0.04+400.00%
Neumora Therapeutics Newsroom
B of A Securities Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA) and Idexx Laboratories (IDXX)
J.P. Morgan Maintains Neumora Therapeutics(NMRA.US) With Hold Rating
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $23 to $30
Hold Rating for Neumora Therapeutics Amid Disappointing Phase 3 Trial Results and High-Risk Pipeline Dependency
Buy Rating Maintained for Neumora Therapeutics Due to Promising MDD Trial Results and Strong Financial Position
RBC Downgrades Neumora Therapeutics to Sector Perform From Outperform, Price Target Is $4
Optimistic Buy Rating for Neumora Therapeutics Despite Recent Clinical Setback
Neumora Therapeutics Analyst Ratings
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $30
Neumora Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
Neumora Therapeutics Analyst Ratings
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $30